Top

International Journal of Clinical Oncology

Published in:

01-10-2019 | Radiotherapy | Original Article

Frequency and predictors of detecting early locoregional recurrence/disease progression of oral squamous cell carcinoma with high-risk factors on imaging tests before postoperative adjuvant radiotherapy

Authors: Yuichi Kibe, Naoki Nakamura, Hirofumi Kuno, Takashi Hiyama, Ryuichi Hayashi, Sadamoto Zenda, Atsushi Motegi, Hidehiro Hojo, Masaki Nakamura, Takaki Ariji, Hajime Oyoshi, Tetsuo Akimoto

Published in: International Journal of Clinical Oncology | Issue 10/2019

Abstract

Background

To clarify the frequency and predictors of detecting early locoregional recurrence/disease progression (LR/DP) during the interval between surgery and postoperative adjuvant radiotherapy with/without chemotherapy in patients with oral squamous cell carcinoma.

Methods

Data on 65 patients who had undergone the initial radical surgery for previously untreated oral squamous cell carcinoma which were scheduled to receive adjuvant radiotherapy with/without chemotherapy were reviewed.

Results

Of the 65 patients, 63 (97%) were margin-positive/close and/or extracapsular extension-positive (hereinafter, high-risk factors). Eighteen (28%) patients had abnormal findings suggestive of LR/DP on postoperative imaging. Fifteen (23%) patients were diagnosed with LR/DP and treatment policy was changed. Univariate and multivariate analyses revealed higher frequencies of abnormal findings suggestive of LR/DP (univariate/multivariate analysis, p = 0.020/0.036), diagnosing of LR/DP, and changing the treatment policy (univariate/multivariate analysis, p = 0.042/0.046), among the patients who underwent postoperative diagnostic imaging tests or radiotherapy-planning contrast-enhanced (CE) CT without diagnostic imaging tests as compared with those who underwent radiotherapy-planning non-CECT without such tests.

Conclusion

The frequency of detecting of early LR/DP before postoperative adjuvant treatment in oral squamous cell carcinoma patients with high-risk factors was high. Furthermore, postoperative diagnostic imaging tests and radiotherapy-planning CECT may be useful to detect early LR/DP in oral squamous cell carcinoma patients before postoperative adjuvant therapy.

Adelstein D, Gillison ML, Pfister DG et al (2017) NCCN guidelines insights: head and neck cancers, version 2.2017. J Natl Compr Canc Netw 15(6):761–770. https://doi.org/10.6004/jnccn.2017.0101 CrossRefPubMed

Bernier J, Domenge C, Ozsahin M et al (2004) Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350(19):1945–1952. https://doi.org/10.1056/NEJMoa032641 CrossRefPubMed

Cooper JS, Pajak TF, Forastiere AA et al (2004) Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350(19):1937–1944. https://doi.org/10.1056/NEJMoa032646 CrossRefPubMed

Bernier J, Cooper JS, Pajak TF et al (2005) Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck 27(10):843–850. https://doi.org/10.1002/hed.20279 CrossRefPubMed

Dutta PR, Riaz N, McBride S et al (2016) Postoperative PET/CT and target delineation before adjuvant radiotherapy in patients with oral cavity squamous cell carcinoma. Head Neck 38(Suppl 1):E1285–1293. https://doi.org/10.1002/hed.24213 CrossRefPubMed

Liao CT, Fan KH, Lin CY et al (2012) Impact of a second FDG PET scan before adjuvant therapy for the early detection of residual/relapsing tumours in high-risk patients with oral cavity cancer and pathological extracapsular spread. Eur J Nucl Med Mol Imaging 39(6):944–955. https://doi.org/10.1007/s00259-012-2103-2 CrossRefPubMed

Shintani SA, Foote RL, Lowe VJ et al (2008) Utility of PET/CT imaging performed early after surgical resection in the adjuvant treatment planning for head and neck cancer. Int J Radiat Oncol Biol Phys 70(2):322–329. https://doi.org/10.1016/j.ijrobp.2007.06.038 CrossRefPubMed

Colevas AD, Yom SS, Pfister DG et al (2018) NCCN guidelines insights: head and neck cancers, version 1.2018. J Natl Compr Canc Netw 16(5):479–490. https://doi.org/10.6004/jnccn.2018.0026 CrossRefPubMed

De Felice F, de Vincentiis M, Valentini V et al (2017) Follow-up program in head and neck cancer. Crit Rev Oncol Hematol 113:151–155. https://doi.org/10.1016/j.critrevonc.2017.03.012 CrossRefPubMed

10.

Gregoire V, Lefebvre JL, Licitra L et al (2010) Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v184–186. https://doi.org/10.1093/annonc/mdq185 CrossRefPubMed

Title: Frequency and predictors of detecting early locoregional recurrence/disease progression of oral squamous cell carcinoma with high-risk factors on imaging tests before postoperative adjuvant radiotherapy
Authors: Yuichi Kibe
Naoki Nakamura
Hirofumi Kuno
Takashi Hiyama
Ryuichi Hayashi
Sadamoto Zenda
Atsushi Motegi
Hidehiro Hojo
Masaki Nakamura
Takaki Ariji
Hajime Oyoshi
Tetsuo Akimoto
Publication date: 01-10-2019
Publisher: Springer Singapore
Keywords: Radiotherapy
Cytostatic Therapy
Published in: International Journal of Clinical Oncology / Issue 10/2019
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-019-01479-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2019

A phase II randomized controlled study of pegylated liposomal doxorubicin and carboplatin vs. gemcitabine and carboplatin for platinum-sensitive recurrent ovarian cancer (GOTIC003/intergroup study)

Phase II study of S-1 on alternate days plus bevacizumab in patients aged ≥ 75 years with metastatic colorectal cancer (J-SAVER)

A single-arm, phase 2 study of steroid-containing mouthwash for the prevention of everolimus-associated stomatitis in multiple tumor types

Immune checkpoint inhibitor-induced sarcoidosis-like granulomas

Thrombotic events induce the worse prognosis in ovarian carcinomas and frequently develop in ovarian clear cell carcinoma

Prognostic factors and survival in Japanese patients with brain metastasis from renal cell cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer